Diagnosis and Clinical Virology of Lassa Fever as Evaluated by Enzyme-Linked Immunosorbent Assay, Indirect Fluorescent-Antibody Test, and Virus Isolation

D. G. BAUSCH,†* P. E. ROLLIN,1 A. H. DEMBY,1 † M. COULIBALY,2 J. KANU,1 A. S. CONTEH,3 K. D. WAGONER,1 L. K. MCMULLAN,1 M. D. BOWEN,†‡ C. J. PETERS,1 AND T. G. KSIAZEK1

Special Pathogens Branch, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; † Present address: Division of AIDS, STD, and TB Laboratory Research, Centers for Disease Control and Prevention, Atlanta, Ga. ‡ Present address: Bioterrorism Rapid Response and Advanced Technology Laboratory, Bioterrorism Preparedness and Response Program, Centers for Disease Control and Prevention, Atlanta, Ga.

Received 14 December 1999/Returned for modification 13 March 2000/Accepted 8 May 2000

The Lassa virus (an arenavirus) is found in West Africa, where it sometimes causes a severe hemorrhagic illness called Lassa fever. Laboratory diagnosis has traditionally been by the indirect fluorescent-antibody (IFA) test. However, enzyme-linked immunosorbent assays (ELISAs) for Lassa virus antigen and immunoglobulin M (IgM) and G (IgG) antibodies have been developed that are thought to be more sensitive and specific. We compared ELISA and IFA testing on sera from 305 suspected cases of Lassa fever by using virus isolation as a positive reverse transcription-PCR (RT-PCR) test as the “gold standard.” Virus isolation and RT-PCR were positive on 50 (16%) of the 305 suspected cases. Taken together, Lassa virus antigen and IgM ELISAs were 88% (95% confidence interval [CI], 77 to 95%) sensitive and 90% (95% CI, 88 to 91%) specific for acute infection. Due to the stringent gold standard used, these likely represent underestimates. Diagnosis could often be made on a single serum specimen. Antigen detection was particularly useful in providing early diagnosis as well as prognostic information. Level of antigenemia varied inversely with survival. Detection by ELISA of IgG antibody early in the course of illness helped rule out acute Lassa virus infection. The presence of IFA during both acute and convalescent stages of infection, as well as significant interobserver variation in reading the slides, made interpretation difficult. However, the assay provided useful prognostic information, the presence of IFA early in the course of illness correlating with death. The high sensitivity and specificity, capability for early diagnosis, and prognostic value of the ELISAs make them the diagnostic tests of choice for the detection of Lassa fever.

Lassa virus is an arenavirus known to cause a severe hemorrhagic fever in West Africa. An estimated 100,000 infections and 5,000 deaths occur yearly across the region (10, 24). Early clinical manifestations are often indistinguishable from those of many other febrile illnesses, making clinical diagnosis difficult (17). The antiviral drug ribavirin is effective, but only if administered early in the course of illness (12, 18). Because of its expense, need for intravenous administration, potential toxicity, and teratogenicity, empiric therapy with ribavirin is undesirable (7, 15, 18). As Lassa virus has been associated with nosocomial outbreaks with high mortality (19, 28), early identification of infected individuals is important for the prompt implementation of appropriate barrier nursing guidelines (8). Thus, for both therapeutic and preventive considerations, a rapid and accurate laboratory test for the diagnosis of acute Lassa fever early in the course of the disease is imperative.

Laboratory diagnosis of acute Lassa virus infection has traditionally employed the indirect fluorescent-antibody (IFA) test (17, 30). This technique has been criticized, however, for a perceived lack of specificity in populations with a low apparent risk of infection (27). In recent years, enzyme-linked immunosorbent assays (ELISAs) for Lassa virus antigen and Lassa virus-specific immunoglobulin M (IgM) and G (IgG) antibodies that are thought to be more sensitive and specific have been developed (11, 13, 22). However, to date, testing with this technique has been conducted only on animals and on a small number of patients known to be infected with Lassa virus. A thorough evaluation of the assay on field-collected samples has not been conducted to assess its true sensitivity and specificity. We therefore performed the Lassa virus antibody and antigen ELISAs on sera from a large number of patients suspected of having Lassa fever from West Africa. As the “gold standard” test of Lassa virus infection, we used isolation of virus as detected by immunofluorescent staining for viral antigen along with a positive reverse transcription-PCR (RT-PCR) test on the isolate. Genetic sequencing was performed on most RT-PCR products to confirm the viruses as strains of Lassa virus. Lastly, recognizing that much previous research on Lassa fever has employed the IFA technique, we examined the relationship between antibodies detected by ELISA and IFA testing. We report here the results and interrelationships of the varied components of these assays and explore how they might best be used in both diagnosis and management of Lassa fever.

MATERIALS AND METHODS

Patient identification and specimen collection. Specimens were collected from patients suspected of having Lassa fever who presented to Kenema Government Hospital in Sierra Leone or to one of four surveillance hospitals in Guinea, West Africa, from October 1996 through February 1998. Blood was drawn immediately upon clinical suspicion of Lassa fever (which was most often at the time of
admission) and then at various intervals over the following weeks. Samples were collected in 10-mL syringes and allowed to clot at ambient temperature for no more than 2 h before the serum was separated by personnel wearing standard protective clothing and gloves. Afterwards, the sera were stored at –70°C until being irradiated with 106 rads (20,000 Gy), fixed in cold acetone for 10 min and was washed once in 0.01 M borate saline, pH 7.2. The slides were read immediately after preparation by using an Axioskop microscope (Zeiss, Oberkochen, Germany) with appropriate barrier and excitation filters. The slides were then incubated for 1 h at 37°C in a humidified chamber and washed for 10 min and was washed once in 0.01 M borate saline, pH 9.0. The slides were then incubated with goat anti-human IgG antibody (Murex Diagnostics Ltd., Dartford, England) at a dilution of 1:500, held overnight at 4°C and then washed, and fourfold serial dilutions of test sera (1:100 to 1:6,400) and were retested. Positive and negative controls were included with each assay. The slides were incubated for 1 h at 37°C in a humidified chamber and washed for 10 min and was washed once in 0.01 M borate saline, pH 7.2. Fluorescein isothiocyanate (FITC)-conjugated sheep anti-human Ig (Murex Diagnostics Ltd., Dartford, England) at a dilution of 1:50 was then applied to the slides and washed three times with PBS containing 0.1% Tween 20. A mock-infected Vero E6 control antigen was similarly prepared.

Microtiter plates were again divided into positive and negative slides and were retested. Positive and negative controls were included with each assay. The slides were incubated for 1 h at 37°C in a humidified chamber and washed for 10 min and was washed once in 0.01 M borate saline, pH 7.2. Fluorescein isothiocyanate (FITC)-conjugated sheep anti-human Ig (Murex Diagnostics Ltd., Dartford, England) at a dilution of 1:50 was then applied to the slides and washed three times with PBS containing 0.1% Tween 20. A mock-infected Vero E6 control antigen was similarly prepared.

Microtiter plates were again divided into positive and negative slides and were retested. Positive and negative controls were included with each assay. The slides were incubated for 1 h at 37°C in a humidified chamber and washed for 10 min and was washed once in 0.01 M borate saline, pH 7.2. Fluorescein isothiocyanate (FITC)-conjugated sheep anti-human Ig (Murex Diagnostics Ltd., Dartford, England) at a dilution of 1:50 was then applied to the slides and washed three times with PBS containing 0.1% Tween 20. A mock-infected Vero E6 control antigen was similarly prepared.

Microtiter plates were again divided into positive and negative slides and were retested. Positive and negative controls were included with each assay. The slides were incubated for 1 h at 37°C in a humidified chamber and washed for 10 min and was washed once in 0.01 M borate saline, pH 7.2. Fluorescein isothiocyanate (FITC)-conjugated sheep anti-human Ig (Murex Diagnostics Ltd., Dartford, England) at a dilution of 1:50 was then applied to the slides and washed three times with PBS containing 0.1% Tween 20. A mock-infected Vero E6 control antigen was similarly prepared.

Microtiter plates were again divided into positive and negative slides and were retested. Positive and negative controls were included with each assay. The slides were incubated for 1 h at 37°C in a humidified chamber and washed for 10 min and was washed once in 0.01 M borate saline, pH 7.2. Fluorescein isothiocyanate (FITC)-conjugated sheep anti-human Ig (Murex Diagnostics Ltd., Dartford, England) at a dilution of 1:50 was then applied to the slides and washed three times with PBS containing 0.1% Tween 20. A mock-infected Vero E6 control antigen was similarly prepared.

Microtiter plates were again divided into positive and negative slides and were retested. Positive and negative controls were included with each assay. The slides were incubated for 1 h at 37°C in a humidified chamber and washed for 10 min and was washed once in 0.01 M borate saline, pH 7.2. Fluorescein isothiocyanate (FITC)-conjugated sheep anti-human Ig (Murex Diagnostics Ltd., Dartford, England) at a dilution of 1:50 was then applied to the slides and washed three times with PBS containing 0.1% Tween 20. A mock-infected Vero E6 control antigen was similarly prepared.

Microtiter plates were again divided into positive and negative slides and were retested. Positive and negative controls were included with each assay. The slides were incubated for 1 h at 37°C in a humidified chamber and washed for 10 min and was washed once in 0.01 M borate saline, pH 7.2. Fluorescein isothiocyanate (FITC)-conjugated sheep anti-human Ig (Murex Diagnostics Ltd., Dartford, England) at a dilution of 1:50 was then applied to the slides and washed three times with PBS containing 0.1% Tween 20. A mock-infected Vero E6 control antigen was similarly prepared.

Microtiter plates were again divided into positive and negative slides and were retested. Positive and negative controls were included with each assay. The slides were incubated for 1 h at 37°C in a humidified chamber and washed for 10 min and was washed once in 0.01 M borate saline, pH 7.2. Fluorescein isothiocyanate (FITC)-conjugated sheep anti-human Ig (Murex Diagnostics Ltd., Dartford, England) at a dilution of 1:50 was then applied to the slides and washed three times with PBS containing 0.1% Tween 20. A mock-infected Vero E6 control antigen was similarly prepared.
fluid in PBS-skim milk at a dilution of 1:100 was added to each spot well, and the slides were incubated at 37°C in a humidified chamber for 1 h. After being washed for 10 min in PBS, pH 7.2, and redried, FITC-conjugated goat anti-mouse IgG (Cappel, Durham, N.C.) in PBS-skim milk at a dilution of 1:50 mixed with 10 μl of 1% Evans blue was added, and the slides were again incubated for 30 min. Finally, slides were washed, mounted, and read as described above. Positive and negative controls were included.

RT-PCR and sequencing. RT-PCR amplification was performed on all specimens from which Lassa virus was isolated. In the BSL-4 laboratory, 300 μl of the remaining cell suspension was added to 1 ml of Tripure reagent (Boehringer Mannheim, Indianapolis, Ind.) to inactivate virus and protect viral RNA from nuclease digestion. The samples were then passed out of the BSL-4 laboratory through the Lysol immersion tank for RNA extraction and RT-PCR. Genetic sequence analysis was performed on most isolates by using a published nucleotide primer pair targeting a region near the 3' end of the arenavirus N gene (3).

Data analysis. Data were analyzed using SPSS version 8.0 statistical software. To account for their nonnormal distribution, viral titers were converted to the log_{10} of their value for statistical analysis. Student's t test, Fisher's exact test, and the kappa correlation coefficient were applied where appropriate.

RESULTS

Patients and specimen collection. A total of 590 serum specimens collected from 305 patients suspected of having acute Lassa virus infection, 224 from Guinea and 81 from Sierra Leone, were evaluated. The mean number of specimens collected per patient was 1.9 (range, 1 to 5 days). The first blood draw was performed a mean of 9.6 days (range, 0 to 57 days) after the reported onset of illness. Patients with confirmed Lassa fever presented to the hospital significantly earlier after the reported onset of illness than those who were virus isolation negative, 7.9 versus 9.9 days (P < 0.05), suggesting that they were more seriously ill.

Virus isolation and RT-PCR. Viral antigens were observed in 12 of 18 specimens scraped 1 week after inoculation and in all 18 after 2 weeks. Combined with the specimens that were scraped only at 2 weeks, Lassa virus infection was confirmed by virus isolation in 50 (16.4%) of the 305 suspected cases, 7 from Guinea and 43 from Sierra Leone. Viral RNA was amplified from all 50 isolates. Genetic sequence analysis performed on 41 (82%) of the 50 isolates confirmed them to be Lassa viruses with moderate heterogeneity. Viruses were not identical to the reference Josiah strain. Details on the molecular analysis will be presented in a subsequent publication. A total of 112 serum specimens were collected from the 50 culture-confirmed cases.

ELISA. (i) Sensitivity and specificity. Figure 1 shows the distribution of ELISA titers and ODs from the first two blood specimens obtained from confirmed cases of Lassa fever. A summary of the serologic results is presented in Table 1.
ELISA of IgM proved to be the single most sensitive assay in detecting acute infection overall, identifying 36 (72%) of the 50 cases. However, antigen detection was more sensitive early in the course of the disease, identifying 15 (30%) of the 50 on the first blood draw (see below). In practice, ELISAs for antigen and IgM are used in tandem, with a case considered positive if ELISA antigen and/or IgM antibody are present. Performed on all 305 suspected cases, ELISA for antigen and IgM (ELISA Ag/IgM) detected 44 (88%) of the 50 culture-confirmed cases for a sensitivity and specificity of 88% (95% confidence interval [CI], 77 to 95%) and 90% (95% CI, 88 to 91), respectively (Table 2).

ELISA IgG antibody was detected in 50 (16%) of the 305 suspected cases, but in only 9 (18%) of the 50 confirmed acute cases of Lassa virus infection. These nine had multiple blood draws (mean 3.6) but were never found to be ELISA IgG antibody positive early in the course of their disease. Titers were significantly higher in the presumed convalescent cases than in the acutely infected cases (mean log10 titer, 3.3 versus 2.7, respectively, \( P = 0.016 \)). Thus, the presence of ELISA IgG antibody confirms previous exposure to Lassa virus and, conversely, can be used to exclude acute infection if found in high titer early in the course of illness. Six (12%) of the 50 patients from whom Lassa virus was isolated were completely negative by all ELISA and IFA testing.

(ii) Time to diagnosis. The timing of antigen and antibody responses relative to symptom onset is shown in Fig. 2. ELISA Ag/IgM detected 56% of the cases on the first serum specimen drawn. Antigen usually appeared in the first week of illness, to be subsequently replaced by IgM antibody in the second week. IgM antibody then typically remained positive through the last drawn sample, which was a mean of 16.4 days (range, 4 to 40 days).
days) after symptom onset. Antigen and IgM almost never appeared concurrently in a single blood draw (1 of 590 specimens), suggesting that IgM either clears viral antigen or masks it from detection. ELISA IgG began to appear around week 3. The mean time from symptom onset until the first positive serologic result for the various diagnostic assays is shown in Table 3.

(iii) ELISA results and prognosis. High titers of Lassa virus have been associated with a poor prognosis (14). However, viral culture and quantitative assay are too time-consuming, expensive, and dangerous in most settings to make this information of practical clinical benefit. We examined whether level of antigenemia could be used as a surrogate, and also investigated the relationship between ELISA IgM and IgG antibodies and prognosis.

Seventeen (24%) of the 50 patients with confirmed Lassa fever died. Death occurred a mean of 13.2 days (range, 4 to 31 days) after symptom onset. Qualitatively, only the absence of IgM antibody was associated with death (Table 4), most likely indicating that the fatalities occurred before the time when IgM antibody usually appears. However, one could alternatively interpret this as a specific defect in IgM antibody response that resulted in death. Although the absolute numbers were perhaps too small to reach statistical significance, patients who were antigen positive were almost twice as likely to die than those who were antigen negative.

The relationship between titer level and survival is presented in Table 5. Mean log_{10} antigen titers were significantly higher in patients who died. Conversely, there was an inverse relationship between death and levels of both IgM and IgG antibodies. This result again most likely simply reflects that death in most of the hospitals, no conclusions can be made regarding its potential effects on outcome, antigen, or antibody titer. Lastly, due to the lack of laboratory facilities in the study hospitals, we were not able to investigate the relationship between Lassa virus antigen or antibody and the level of aspartate aminotransferase. This relationship would be important to explore, as aspartate aminotransferase levels over 150 IU/liter have also been shown to correlate inversely with survival (14).

IFA. IFA testing was less sensitive than ELISA Ag/IgM, detecting 35 (70%) of the 50 culture-confirmed cases of Lassa fever (Table 6). The profile of IFA responses was quite similar to that of the combined ELISA IgM and IgG results, indicating the cross specificity of the IFA conjugate for IgM, IgG, and IgA isotypes (kappa = 0.686; P < 0.001) (Fig. 3). The time from symptom onset until appearance of IFA was also similar to that of ELISA IgM antibody (Table 3). Interestingly, IFA appeared significantly earlier in patients with fatal cases than in survivors (9.3 versus 14.1 days, respectively; P < 0.05).

The interpretation of IFA results was considerably observer dependent. While sensitivity and specificity were maintained with the observer of intermediate experience, they fell to 62% (95% CI, 49 to 74%) and 71% (95% CI, 68 to 73%), respectively, when the slides were read by novices. However, this difference appears to be largely overcome as observers gain experience. The interpretations of the expert and intermediate observers were almost identical. Exactly how this would translate to the field and at what point a novice observer becomes “competent” would obviously vary with the setting and personnel. Although we did not formally examine this in our study, it is our observation that there is often significant intraobserver variation as well. Lastly, it should be noted that, short of photographing each microscopic field, no objective permanent record is produced from IFA testing. Thus, results cannot be reviewed should future questions arise.

### Table 3. Time from reported symptom onset until the first blood draw positive for Lassa fever with various diagnostic modalities

<table>
<thead>
<tr>
<th>Assay</th>
<th>No. cases positive (+ SEM)</th>
<th>Mean no. days Range (days)</th>
<th>ELISA IgG 0.9 (0.9) 29 (88)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELISA antigen</td>
<td>18</td>
<td>7.9 (0.8)</td>
<td>3–15</td>
</tr>
<tr>
<td>ELISA IgM</td>
<td>36</td>
<td>13.1 (0.9)</td>
<td>4–31</td>
</tr>
<tr>
<td>ELISA IgG</td>
<td>9</td>
<td>25.6 (3.0)</td>
<td>7–39</td>
</tr>
<tr>
<td>IFA</td>
<td>34</td>
<td>13.1 (1.0)</td>
<td>4–31</td>
</tr>
<tr>
<td>Virus isolation</td>
<td>50</td>
<td>8.0 (0.6)</td>
<td>3–22</td>
</tr>
</tbody>
</table>

### Table 4. Presence of Lassa virus antigen or antibody and outcome in 50 patients with virus culture-confirmed Lassa fever (percentages are of the total in each column)

<table>
<thead>
<tr>
<th>Positive assay</th>
<th>No. positive samples from patients that died (n = 17) (%)</th>
<th>No. positive samples from patients that survived (n = 33) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELISA antigen</td>
<td>9 (53)</td>
<td>9 (27)</td>
</tr>
<tr>
<td>ELISA IgM</td>
<td>7 (41)</td>
<td>29 (88)</td>
</tr>
<tr>
<td>ELISA IgG</td>
<td>1 (6)</td>
<td>8 (24)</td>
</tr>
<tr>
<td>IFA</td>
<td>9 (53)</td>
<td>26 (79)</td>
</tr>
</tbody>
</table>

### Table 5. Mean log_{10} peak titer of antigen or antibody and outcome in 50 patients with virus culture-confirmed Lassa fever

<table>
<thead>
<tr>
<th>Assay</th>
<th>Mean log_{10} peak titer (SEM) for patients that: Died (n = 17)</th>
<th>Survived (n = 33)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELISA antigen</td>
<td>0.99 (0.24)</td>
<td>0.41 (0.12)</td>
</tr>
<tr>
<td>ELISA IgM</td>
<td>1.47 (0.40)</td>
<td>3.25 (0.22)</td>
</tr>
<tr>
<td>ELISA IgG</td>
<td>0.31 (0.22)</td>
<td>0.98 (0.25)</td>
</tr>
<tr>
<td>IFA</td>
<td>1.38 (0.33)</td>
<td>2.27 (0.22)</td>
</tr>
</tbody>
</table>

### Table 6. Results of IFA compared with virus isolation for 305 suspected cases of Lassa fever

<table>
<thead>
<tr>
<th>Virus isolation</th>
<th>No. IFA (% total cases)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Negative</td>
</tr>
<tr>
<td>Negative</td>
<td>223 (73.1)</td>
</tr>
<tr>
<td>Positive</td>
<td>15 (4.9)</td>
</tr>
<tr>
<td>Total</td>
<td>238 (78.0)</td>
</tr>
</tbody>
</table>

*p < 0.001 between survivors and deaths.*
DISCUSSION

Our results show the combined ELISA Ag/IgM assay to be highly sensitive and specific for the diagnosis of Lassa fever. The antigen detection assay offers a particular advantage in providing early diagnosis as well as prognostic information.

Although we used virus isolation as the gold standard for detection of Lassa virus infection, virus cannot be uniformly isolated from all acute cases, especially when the sample is obtained late in the course of illness (14). Furthermore, although Lassa virus is relatively hearty when stored in serum (D. G. Bausch, unpublished observation), breaks in the cold chain in Sierra Leone, where the majority of the cases were from, may have resulted in the deterioration of Lassa virus while the more heat-stable antibodies remained. This would result in apparent false-positive serologic results.

IgM antibody, but not Lassa virus antigen, was detected in 23 (88%) of the 26 cases reported as false positives in Table 2. A strong argument can be made that these were, in fact, true positives from whom blood was obtained only after the period of viremia. Twelve (63%) of the 19 cases from this group who had more than one specimen obtained showed rising IgM titers consistent with recent exposure to Lassa virus. Furthermore, ELISA IgG seroconversion was documented in 9 (82%) of the 11 who had three or more blood draws. If we consider these 23 cases as true positives, the sensitivity and specificity of the ELISA Ag/IgM would increase to 92% (95% CI, 86 to 95%) and 99% (95% CI, 97 to 100%), with positive and negative predictive values of 96% (95% CI, 89 to 99%) and 97% (95% CI, 96 to 98%), respectively. We believe these numbers to be more reflective of the true capabilities of the assay.

It was probably too late in the illness for these virus-negative, IgM-positive patients to benefit from ribavirin therapy. However, the exact mechanism of action of ribavirin in Lassa fever is unknown, and immunomodulatory effects of the drug have been reported that may confer benefit independently of any direct effects on virus replication (23). Twenty-one (91%) of the 23 virus-negative, IgM-positive patients survived. Five (22%) received ribavirin. One of the two patients who died received the drug.

Even if specific antiviral therapy would no longer be efficacious, confirming the diagnosis of Lassa fever is imperative. It allows the clinician to abandon an extensive search for other entities, to initiate rodent control measures in the patient’s home to prevent infection of other family members, and to counsel the patient regarding behavior after discharge from the hospital. This latter point is important because Lassa virus has been isolated from throat swabs taken after viremia has ended (14, 20) and from semen as long as 6 weeks after acute disease (9). Anecdotal cases of Lassa virus transmission through sexual contact weeks to months after hospital discharge have been noted (A. H. Demby, personal communication). Lastly, ruling out Lassa fever spares the patient the expense and potential toxicity of ribavirin therapy.

ELISA Ag/IgM testing affords the advantage of often providing a diagnosis via a single serum specimen. Thus, diagnoses can be made on patients who would otherwise be missed be-
cause of short hospital stays, infrequent outpatient follow-up, or refusal of repeated phlebotomy. Furthermore, the costs and risks associated with repeated needle sticks and laboratory evaluation are avoided. It should be noted, however, that the surest diagnosis is still provided by the testing of both acute- and convalescent-phase sera.

Since the samples for this study were collected under field conditions, we are limited in the conclusions that can be drawn regarding the profiles of antigen and antibody responses. The timing of patient presentation and phlebotomy were variable, as was the reliability of patient histories from which the date of onset of illness was obtained. These limitations may have affected our conclusions. For example, using the results of the first blood draw, we found that antigen detected by ELISA appeared a mean of 7.9 days after symptom onset. However, 10 (31%) of the 32 antigen negative cases did not have blood drawn until after day 10. Thus, the prevalence of antigen-positive patients would likely be much higher, and the time from symptom onset until presentation of antigen would be shorter, if patients could have presented or been tested earlier in the course of their illness. Lastly, as samples for this study were drawn only within a few weeks after symptom onset in an attempt to diagnose acute infection, no conclusions can be made regarding the duration of IgM or IgG antibodies.

Of interest are the six seronegative patients from whom Lassa virus was nevertheless isolated. The reasons for this finding are unclear. Serologic testing and virus isolation were repeated multiple times to ensure accurate results. No obvious common factors were apparent in these cases with respect to age, sex, time from symptom onset until presentation, survival, or receipt of ribavirin. Host genetic factors, such as those resulting in vigorous cytotoxic T-lymphocyte responses, or concomitant immunocompromised states such as AIDS or malnutrition may have altered the profile of the antigen and antibody responses.

We considered that direct cross contamination of tubes during collection in the field could account for this finding. However, genetic sequencing performed on four of the six isolates revealed each to be unique among the 41 sequenced genomic fragments. Variation at the nucleotide level ranged from 0.3 to 5.3%. Conversely, it seems unlikely that this relatively minor degree of genetic variation would result in these viruses presenting epitopes unrecognized by the antigen detection ELISA developed with the Josiah reference strain of Lassa virus.

We did not determine viral titers in our study. However, we postulate that some samples drawn early in the course of illness, before the onset of antibody production, may have contained levels of virus below the threshold of detection of the antigen-capture ELISA but which could nevertheless be propagated by culture. This possibility could be the explanation for two of these six seronegative patients who had only single specimens drawn at days 5 and 7. However, the others each had two samples drawn, at times ranging from days 4 to 18, which would seem to be adequate to detect antigen and/or antibody.

A last possibility is that these six patients had an equilibrium of antigen and IgM antibody and thus no available binding sites for detection on the ELISAs. Perhaps a dissociation step is necessary to allow detection.

Various measures might be employed to improve the sensitivity and specificity of the IFA assay, such as the use of IgM- and IgG-specific conjugates (29), although high background often makes interpretation difficult, and even conjugates from reputable suppliers may not be sufficiently isotype specific (P. E. Rollin, personal communication). In contrast to ELISA, the IgG antibody detected by the IFA assay is produced during the course of acute Lassa virus infection (17, 29), which may make the distinction between acute and previous exposure difficult. This risk is particularly high in areas of eastern Sierra Leone, southeastern Guinea, western Liberia, and the Jos plateau of Nigeria, where Lassa virus transmission is highly endemic (1, 2, 21, 24). Criteria such as a fourfold increase in titer between acute- and convalescent-phase sera or a single serum specimen with high titer have been used to help distinguish between acute infection and previous exposure (17, 30). However, these measures would still be unlikely to render IFA testing as sensitive as ELISA, whose main sensitivity advantage is conferred by the detection of antigen. The IFA test might prove useful should one want to perform a single-assay survey for any previous exposure to Lassa virus, including very recently infected individuals along with those exposed in the past.

The association between death and the early appearance of IFA antibody was unexpected. No such association was noted between survival and ELISA antibodies. If the association is real, it might suggest an immunopathogenic mechanism of severe Lassa fever, as has been well described in animal models of another arenavirus infection, lymphocytic choriomeningitis virus (4, 5). If this is the case, antibody may either be the primary effector or, perhaps more likely, represent a surrogate for a cell-mediated immunopathologic response.

Various diagnostic methods are available for the study of Lassa fever. Although virus isolation remains the most sensitive, it is still uniquely a research tool. Sensitive RT-PCR assays exist, but issues of strain variation, cross contamination, and expense pose practical problems for use in the developing countries where Lassa fever is endemic (6, 16, 26). A rapid diagnostic immunoblot assay for Lassa fever has recently been developed, but its usefulness is limited by its low sensitivity (25), nor would it provide the prognostic information available from the antigen ELISA or IFA. The interpretation of IFA results is complicated by the presence of IFA during both acute and convalescent stages of infection and by the subjective nature of the assay. However, the appearance of IFA antibody early in the course of Lassa infection may be useful in identifying patients with poor prognoses. ELISA Ag/IgM comprises the most sensitive and specific serologic test for acute Lassa virus infection and provides useful prognostic information. An additional advantage of ELISA-based diagnostics is their applicability to the diagnosis of numerous other diseases prevalent in developing countries, such as AIDS, typhoid fever, and the hepatitis viruses.

ACKNOWLEDGMENTS

This work was supported by a grant from the American Association of Schools of Public Health in conjunction with the Tulane School of Public Health and Tropical Medicine, Department of Tropical Medicine, New Orleans, La.

We thank Alpha Bah, Rilvane Bah, Adama Seray Barry, Fatoumata Binta Balde, Ibrahima Camara, Sekou Cissé, Mohammed Ciré Diallo, Rouguiatou Diallo, Ishmaci Doukare, Djécondé Fofoña, Steven Gbogorie, Augustine Goba, Barry Mahy, Kabba Siddité, Robert Tamba Tolno, and Michel Tournakara for their laboratory, clinical, and logistic support in Guinea; Sidiki Safia for laboratory support in Sierra Leone; Debbie Cannon, Heather Hustad, Rich Meyer, Pat Stockton, Kathy Veilleaux, Linda Pezzanite, and Thomas Stevens for their laboratory support at CDC; Kathy Cavallaro, Barney Cline, and Ethleen Lloyd for administrative support; and Laura Morgan for help with data management.

REFERENCES
